Formal Japanese approval for Nexavar in liver cancer
This article was originally published in Scrip
Executive Summary
Japan's ministry of health, labour and welfare has granted formal final approval to Bayer/Onyx Pharmaceuticals' Nexavar (sorafenib) for the additional indication of unresectable hepatocellular carcinoma (HCC).